The Challenge in Biologics Manufacturing
Biologics manufacturing, a cornerstone of modern biopharmaceutical manufacturing, depends on one foundational asset: the cell bank. Every production run traces back to a qualified cell line, most commonly a Chinese Hamster Ovary (CHO) cell bank, and the health, consistency, and functional quality of that bank directly determines whether the resulting protein meets specification and achieves optimal manufacturing yields.
Yet cell bank qualification and in-process monitoring still rely heavily on assays that are slow and antiquated. Standard viability stains tell you whether a cell is alive, not whether it is a high-quality producer. Flow cytometry requires labeling and fixation, altering the very cells you are trying to characterize. And by the time traditional analytics flag a problem, whether that’s a declining cell bank, a drifting culture, or a batch trending toward low titer, the process has often already moved too far downstream to correct course economically.
For biologics developers and manufacturers, this gap carries real operational and financial consequences: without a way to assess cell quality early or track functional performance throughout production, teams risk weak banks entering the process, lower yields, higher COGS, and significant wasted time and resources. The industry needs a faster, earlier, non‑destructive measure of cellular health — one that protects productivity, reduces failure rates, and keeps protein‑producing capacity on track before downstream issues emerge.
Speak To A Laser Force Cytology Expert
How Radiance Strengthens Biologics Manufacturing
Radiance®, powered by Laser Force Cytology™, with ISO published methods ISO 16921-2 (Gene Delivery – Quantification Methods for Viral Vectors) and ISO 8934-1 (Biotechnology – Cell Viability Analytical Methods) give biologics teams a real-time, label-free window into single-cell health and function, at the exact points in the workflow where that insight matters most: cell bank qualification, in-process monitoring, predicting downstream product quality, and potency.
Because Laser Force Cytology measures the intrinsic optical and fluidic force signatures of each cell, it captures subtle biochemical and biophysical changes tied to vitality and functional cell state well before those changes show up in traditional viability or a titer assays. There are no dyes and no antibodies to distort the biology you are trying to understand. That means the data reflects what your cells are actually doing, in real time, at the single-cell level.
Key challenges Radiance® helps biologics teams solve:
- Judging the quality of a CHO cell bank before committing it to a production run
- Detecting early shifts in cell vitality that predict declining protein output
- Reducing reliance on lagging, end-point assays for process decisions
- Building a functional, quantitative picture of cell health for regulatory and quality documentation
- Applying consistent, label-free analytics across banking, scale-up, and production
| Traditional Flow Cytometry & Viability Stains | Radiance® (Laser Force Cytology) | |
| Sample prep | Requires dyes, antibodies, or fixation | Label-free, minimal prep |
| What it measures | Live/dead status only | Functional vitality and biochemical and biophysical phenotypic signatures |
| Timing | Endpoint or batch snapshot | Real-time, continuous monitoring |
| Impact on the sample | Alters or destroys the cells being measured | Preserves native cell state |
CHO Cell Bank Qualification You Can Act On
Before a CHO cell bank ever reaches a bioreactor, its quality has to be established with confidence. Radiance® provides a direct, functional readout of cell health at the single-cell level, giving teams a more complete basis for qualifying a bank than viability percentage alone. Rather than relying solely on whether cells are alive, developers can evaluate the biochemical and biophysical signatures associated with a healthy, productive population, so the decision to move a bank into production is grounded in functional data, not just a pass/fail viability threshold. This is especially valuable during CHO cell line development, when teams are often screening dozens of candidate clones to identify the strongest producer. Radiance’s single-cell resolution helps differentiate high-performing populations early, before resources are committed to scale-up.
This matters because a cell bank is not just a starting material, it is the biological foundation the entire production process is built on. Catching quality issues at the banking stage, rather than discovering them mid-run, protects downstream timelines and avoids the cost of a failed or underperforming batch.
Ensuring Protein Production and Titer Yield
Biologics are only as strong as the cells that produce them. Radiance® helps teams safeguard protein production and titer yield by revealing functional, single‑cell vitality trends long before they appear in end‑point titer or product‑quality assays. This early insight shows whether a culture is on track to deliver the yield and quality a program requires.
Instead of discovering at harvest that a batch underperformed, teams can identify at‑risk cultures earlier in the run — when there is still time to intervene, adjust conditions, or make informed decisions about continuing a batch. This shift from reactive troubleshooting to predictive control reduces variability, prevents wasted time and resources, and strengthens overall manufacturing performance.
Cellular PAT: Real-Time In Process Monitoring, Supporting Advanced Quality Control Strategies
The FDA’s Process Analytical Technology (PAT) framework encourages manufacturers to build quality into a process by continuously monitoring the Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) that define product consistency, rather than relying solely on end-of-batch testing. Radiance® fits naturally into this approach by providing continuous, label-free cell culture monitoring and insight into protein-producing capacity throughout the bioprocess, from seed train through production.
This kind of in-process monitoring supports tighter process control, faster troubleshooting, and a stronger data package for process understanding, whether a program is still in development or already operating under a defined control strategy. For biologics manufacturers working to strengthen their PAT approach, Laser Force Cytology offers a functional, real-time layer of insight that complements existing analytics rather than replacing them outright.
Proven Impact for Biologics Developers
Radiance® is demonstrating measurable, program‑level impact for biologics teams by delivering earlier, functional insight into the cells that drive protein production and titer yield. Organizations using Radiance® across CHO and other producer‑cell workflows have shown:
- More confident cell bank qualification grounded in functional single‑cell data
- Earlier detection of vitality shifts tied to declining productivity
- Reduced reliance on end‑point assays for critical process decisions
- Stronger, more robust regulatory data packages that mitigate risk and support successful quality and regulatory review
Together, these capabilities help prevent batch failures, protect production timelines, reduce wasted time and resources, and lower COGS — the kind of operational and financial impact that matters as much as the underlying science.
The same precision that strengthens CHO cell bank qualification also supports adjacent workflows across cell and gene therapy and vaccine manufacturing, where cell health, functional consistency, and early predictive insight are equally critical to product quality. To see how label-free analytics are being applied across the broader biomanufacturing landscape, visit LumaCyte’s blog.
Alignment With Emerging Global Quality Standards
LumaCyte’s approach is grounded in the direction global standards bodies are moving. In 2026, its label‑free optical and fluidic force method was incorporated into ISO 8934‑1, the international standard for cell‑state and viability assessment across biologics and cell therapy manufacturing. This standard highlights the need for predictive, fit‑for‑purpose analytics capable of detecting functional changes earlier than traditional viability methods — precisely the capability Radiance® delivers.
For teams navigating GMP and evolving regulatory expectations, this alignment provides added confidence that Radiance®’s methodology reflects where the industry is heading: toward earlier, more functional, and non‑destructive measures of cellular health that strengthen manufacturing control and reduce risk.
LumaCyte’s approach to real-time cell vitality monitoring is detailed in the tech note Optimizing Cell Viability in Continuous and Batch Bioprocessing Through Real-Time Monitoring with Laser Force Cytology™. This research shows how Laser Force Cytology reveals changes in cell health metrics long before they appear in standard viability tests, offering a practical model for how the same real-time, label-free approach can strengthen process control and quality decisions across CHO-based biologics manufacturing. Explore the full library of tech notes for additional application data across bioprocess and production workflows.
Frequently Asked Questions About Biologics Manufacturing Analytics
How is Laser Force Cytology used to qualify a CHO cell bank?
Laser Force Cytology™ (LFC™) enables a fast, functional, and highly predictive qualification of CHO cell banks by measuring each cell’s intrinsic optical and fluidic force signatures — no labels, dyes, or antibodies required. This gives teams a direct readout of true cellular vitality and functional potential rather than relying on viability percentage alone.
Radiance® makes this workflow practical in real manufacturing environments:
- Ten‑minute sample prep with no staining or complex handling
- Five‑minute time‑to‑result per sample for rapid decision‑making
- Functional single‑cell metrics that correlate with protein‑producing capacity and downstream performance
By connecting these functional signatures to real productivity outcomes, Radiance® enables a more robust, predictive qualification of CHO cell bank performance — helping teams select stronger banks, avoid weak starting material, and reduce the risk of downstream yield loss.
Can Radiance® predict protein production quality before harvest?
Yes. Radiance® provides a rapid, in‑process protein titer assay that gives teams a clear, quantitative view of production performance well before harvest — helping identify the best harvest day to maximize protein and overall production yield. In addition to direct titer measurement, Radiance® ability to deliver label-free single-cell vitality signatures at the beginning of a production run provides teams a unique predictive understanding early in the process of both how much protein is being produced as well as a measure on how well the cells are functioning. This combined view supports confident, early production decisions long before downstream harvest assays are available.
Key titer‑focused capabilities include:
- Ten‑minute sample prep with no staining or reagents
- Five‑minute time‑to‑result per sample for frequent, upstream checks
- Rapid, label‑free titer assay that quantifies protein production during the run
- Optimal harvest day selection based on real‑time titer trends rather than end‑point guesswork
By providing fast, quantitative titer measurements throughout the culture, Radiance® enables teams to choose the ideal harvest day, maximize production yield, and maintain precise understanding of titer performance long before traditional assays are available.
What role does Radiance® play in a cellular PAT strategy?
Radiance® supports Process Analytical Technology initiatives by providing continuous, real-time, label-free monitoring of cell vitality and functional state throughout a bioprocess. This in-process visibility complements existing analytics and strengthens process understanding and control from seed train through production.
Why is label-free analysis important for biologics manufacturing?
Traditional assays often require dyes, antibodies, or fixation, which can alter the biology being measured and introduce variability. Because Laser Force Cytology requires no labels, it preserves the native state of the cell, giving developers a more accurate picture of true cell health and function in real time.
This matters beyond just a single snapshot. Since the cells remain unaltered and viable after analysis, the same population can continue through the manufacturing process, meaning the measurements reflect what the cells will actually do downstream, not just what they look like at the moment of testing. This allows label-free analysis to serve a predictive role, helping developers anticipate how a batch will perform, flag potential quality issues before they propagate, and make informed go/no-go decisions earlier in the process. Rather than relying solely on retrospective quality checks, manufacturers gain forward-looking insight into cell health and functional potential, supporting more consistent outcomes and reducing the risk of late-stage batch failures.
Is Radiance® specific to CHO cell lines, or does it apply to other biologics manufacturing systems?
While CHO cell bank qualification is one of the most common applications in biologics, Radiance® is not limited to a single cell line or production system. Its label-free, single-cell approach applies broadly across mammalian cell culture platforms used in recombinant protein and monoclonal antibody production.
Has LumaCyte's technology been recognized in any regulatory or industry standards?
Yes. LumaCyte’s label-free optical and fluidic force methodology was incorporated into ISO 8934-1, the international standard for cell viability analytical methods, which specifically addresses cellular state assessment across biologics and cell therapy manufacturing. This builds on LumaCyte’s earlier inclusion in ISO 16921-2 for viral vector quantification, reinforcing Laser Force Cytology as a recognized analytical approach.
Ready to Strengthen Your Biologics Manufacturing?
Gain real-time, label-free insight into cell bank quality, vitality, and protein production, so decisions are based on function, not just a viability count.
